Pediatric recipients (n = 25) of an allogeneic bone marrow (BM) graft were selected on the basis of informative IgG allotype (Gm) differences between the BM donor and the recipient. To investigate the kinetics of the appearance of IgG of donor origin and the disappearance of IgG of recipient origin, G l m and G2m allotype levels were quantified in sera obtained at regular intervals between 3 months and 5 years after BM transplantation (BMT). For this quantification, a dot immunobinding assay (DIBA) has been developed. In 19 of 22 informative recipients, the Gm allotype distribution had reached the range of values expected on the basis of the Gm phenotype of the donor within 6 months after BMT. Remarkably, lgG of recipient origin persisted in 15 of 18 informative recipients until last follow up, ie, for several years after BMT. In addition to the origin of total IgG production, LLOGENEIC BONE marrow transplantation (BMT) is applied for the treatment of hematologic malignancies, severe aplastic anemia (SAA), and congenital diseases. Chimerism studies are important to document engraftment or rejection and to get an insight into the immune reconstitution. The origin of cells of the B-cell lineage can be investigated by analysis of polymorphic epitopes (allotypes) of immunoglobulins (Ig) in case the donor and the recipient of the graft express a different phenotype."6 Hemagglutination inhibition (HAI) assays, routinely used in this respect, allow only semiquantitative measurement of Ig allotype levels in serum.' The generation of monoclonal antibodies (MoAbs) specific for allotypes of IgG heavy chains (Gm allotypes) offered the possibility t o develop quantitative assays. Determination of the quantity of Gm allotypes in serum of recipients early after BMT is hampered by plasma transfusions and Ig suppletion. However, sera of BM graft recipients frequently contain transient homogeneous Ig components (H-Ig).X~'" These H-Ig are mostly of low concentration, appear within weeks after BMT, and are absent from the administered Igcontaining blood products. The kinetics of the appearance of H-Ig suggests that they represent expansions of B-cell clones of donor origin.
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LLOGENEIC BONE marrow transplantation (BMT) is
applied for the treatment of hematologic malignancies, severe aplastic anemia (SAA), and congenital diseases. Chimerism studies are important to document engraftment or rejection and to get an insight into the immune reconstitution. The origin of cells of the B-cell lineage can be investigated by analysis of polymorphic epitopes (allotypes) of immunoglobulins (Ig) in case the donor and the recipient of the graft express a different phenotype."6 Hemagglutination inhibition (HAI) assays, routinely used in this respect, allow only semiquantitative measurement of Ig allotype levels in serum. ' The generation of monoclonal antibodies (MoAbs) specific for allotypes of IgG heavy chains (Gm allotypes) offered the possibility t o develop quantitative assays. Determination of the quantity of Gm allotypes in serum of recipients early after BMT is hampered by plasma transfusions and Ig suppletion. However, sera of BM graft recipients frequently contain transient homogeneous Ig components (H-Ig).X~'" These H-Ig are mostly of low concentration, appear within weeks after BMT, and are absent from the administered Igcontaining blood products. The kinetics of the appearance of H-Ig suggests that they represent expansions of B-cell clones of donor origin.
In the present retrospective study, levels of IgG subclasses and Gm allotypes were quantified in sera obtained from BM graft recipients at regular intervals within the period of 3 the origin of homogeneous IgG components (H-lgG) appearing after BMT was investigated. H-lgG of donor origin could be detected as early as 3 weeks after BMT, but also H-IgG of recipient origin were present in 8 of 13 informative recipients for a period of up t o 1 year after BMT. We conclude that host-type IgG-producing cells were not eradicated by the (myeloablative) conditioning regimen and persisted in a high number of graft recipients. It is our hypothesis that lack of graft-versus-host disease (GVHD) in the majority of these recipients results in the persistence of IgG-producing cells of host origin. These observations may be relevant for the evaluation of patients who received allogeneic BMT for the treatment of multiple myeloma. 0 1996 by The American Society of Hematology. months up to 5 years after BMT. In addition, H-Ig of the IgG isotype (H-IgG) were characterized for their IgG subclass and Gm allotype in sera obtained at 3 weeks after BMT and later. The results indicate that a minor but substantial part of serum IgG was still of recipient origin in 15 of 18 informative recipients at l year after BMT and, in 1 1 of 13 of these cases, at last follow up between 3 and 8 years after BMT, despite engraftment of the donor B-cell lineage. This IgG of recipient origin can be either heterogeneous or of restricted clonal diversity. In addition, Gm allotyping of HIg early after BMT was helpful in determining the origin of cells of the B-cell lineage, especially in cases where administration of Ig-containing blood products interfered with the quantification of Gm allotypes.
MATERIALS AND METHODS

Patients.
Twenty-five pediatric recipients of an allogeneic BM graft were included in this study. They were selected because of the existence of informative IgG allotype (Gm) differences between the BM donor and the recipient and the possibility for a follow-up period of at least 1 year after BMT. Relevant characteristics of the patients (ie, the original disease, the Gm phenotypes of the donor and the recipient as determined by HA1 assays, the pretreatment for BMT, the time period of plasma transfusions andor Ig suppletion, and the occurrence of acute graft-versus-host disease (GVHD) =grade 2 or extensive chronic GVHD) are given in Table 1 . All patients received an unmodified BM graft while staying in the protective environment of a laminar flow isolator and after antimicrobial suppression of their intestinal microflora.I3 Sera were obtained from the donor before BMT and from the recipient before and at regular intervals (3. 6, and 9 weeks: 3, 6, and 9 months; and I , 2, 3, 4, and 5 years) after BMT. The sera were stored at -20°C until investigation.
Quant$cation. Serum levels of IgG subclasses were determined by enzyme-linked immunosorbent assay (ELISA) or dot immunobinding assay (DIBA), as described elsewhere.I4 Gm allotypes were quantified by DIBA using the MoAbs listed in Table 2 . The specificity and usefulness of these MoAbs in (semi-) quantitative assays have been extensively reported."' Some of the MoAbs directed against Gm allotypes are known to show crossreactivity with other IgG subclasses and Gm allotypes, depending on the technique and the dilution in which they are applied. Consequently, for each of the MoAbs, conditions had to be defined to obtain optimal signalnoise ratios. In addition to serum samples under investigation, two reference sera with known amounts of the IgG subclasses were obtained from individuals homozygous for the Gm (za(x);..;g) and for the Gm (f;n; b) haplotypes, respectively. Simultaneous investigation of these reference sera and serum samples of donors and recipients not only served as a specificity control, but also allowed the construction of a standard curve for the calculation of the level of a distinct Gm allotype in the samples to be analyzed.
Quantification of Glm allotypes by DIBA was validated against a radial immunodiffusion (RID) assay, developed by one of us
. In both techniques, 45 sera obtained from recipients after allogeneic BMT were investigated. These sera were selected because they contained IgGl heterozygous for the G l m allotypes and because the concentration of the products of the various Glm alleles was quite variable. Linear regression analysis showed a good correlation between the data obtained by DIBA and RID: Glm(z): Table 2 . The sensitivity limit of detection of H-Ig by WIBL is between 0.5 and 5.0 pg/mL." The WIBL patterns were independently interpreted by two investigators. Only H-IgG, which were detected in immunoblotting patterns for the IgG subclasses and which were also present at the same electrophoretic mobility in immunoblotting patterns for the corresponding Gm allotypes, were taken into consideration. This approach enabled us to apply the crossreactive MoAbs recognizing the G3m allotypes successfully in WIBL. For IgG2, this strategy could not be followed, because antibodies specific for the product of the G2m(..) allele are not available. allotypes and their applicability in DIBA was assessed by testing the MoAbs at various dilutions on sera obtained from individuals homozygous for the Gm (za(x); ..;g) and for the Gm (f; n; b) haplotype, respectively. For each of the MoAbs used at optimal dilutions (Table 2 ), a background signal was observed in sera negative for the relevant Gm allotype. A distinct Gm allotype was considered to be absent from a serum sample when the Glm(z), Glm(a), and Glm(f) levels were below 5%, O S % , and 0.5% of the concentration of total IgG1, respectively, and when the G2m(n) level was below 5% of the concentration of total IgG2 (Table 3) . For G3m(g) and G3m(b), these values were 25% and 45% of the concentration of total IgC3, respectively (Table 3) . Because of these high cut-off levels for negative individuals, it was decided that quantification of the G3m allotypes by DIBA using these MoAbs was not feasible. It has been described that the Glm(a), G2m(n), and G3m(b) alleles contribute more to the production of the corresponding IgG subclass in heterozygotes than the Glm(f), G2m(..), and G3m(g) alleles, respectively.'".'' In sera of heterozygous individuals, the contribution of distinct Gm allotypes to the level of the corresponding IgG subclasses was defined (Table 3) . Finally, in homozygous individuals, the concentration of the positive Gm allotypes was compared with the amount of the corresponding IgG subclasses, and the ranges are given in Table 3 . Deviation from the expected 100% value must be ascribed to experimental variance of the independent determinations.
RESULTS
Gm allotype levels in homozygous and heterozygous individuals. The specificity of the MoAbs directed against Gm
AppearanceofIgGofdonororiginafterBMT. Determination of Gm allotypes to investigate B-cell engraftment is theoretically most informative when the BM donor expresses Gm allotypes, which are not produced by the recipient. Regarding Glrn allotypes, this was the case in 10 of the 25 BMT couples of our study group ( Table 1) . The distribution of the Glrn allotypes was determined longitudinally from 3 months up to 2 years after BMT in the sera from 9 of these IO BM graft recipients. For the two recipients with a homozygous donor (recipients 15 and 20), the proportion of IgGl of donor Glrn allotype versus total IgGl reached the range of homozygous individuals (Table 3 ) between 3 and 12 months after BMT (Fig 1) . It should be noted that in recipient 15 the proportion of donor-derived IgGl dropped below this range at 2 years after BMT because of partial recovery of IgGl production by cells of recipient origin (see below). In six of seven recipients with a heterozygous donor, the relative contribution of IgGl of donor Glm allotype to the level of total IgGl was within the range of heterozygous individuals at 3 (n = 3), 6 (n = 2), and 12 (n = 1) months after BMT, respectively, and later (Fig l ) . The one except' Ion was recipient 9, with graft rejection and recovery of autologous hematopoiesis. IgGl of Glm(f) allotype, indicating donor origin, was almost completely undetectable in serum of this recipient at 6 months after BMT and later.
In addition, 10 recipients who were heterozygous for G 1 m allotypes received a BM graft from a Glrn homozygous donor. In 9 of these I O cases, the proportion of IgGl of donor Glm allotype reached the range of homozygous individuals at 6 months after BMT, and in one case, at 12 months after BMT (data not shown).
With respect to IgG2, there were five G2m(..) recipients with a G2m(n) homozygous (n = 2) or heterozygous (n =
3) donor in our study group (Table 1) . Furthermore, three G2m(n) heterozygous recipients had a G2m(n) homozygous donor. At 3 months after BMT, four of four recipients, longitudinally investigated after BMT, showed G2m allotype levels within the corresponding range of homozygous or heterozygous individuals. In recipient 9 with graft rejection and recovery of autologous hematopoiesis, the appearance of IgG2 of donor origin was only transient (data not shown).
Persistence oj' IgG qf recipient origin after BMT. Twelve BM graft recipients expressed Glrn allotypes that were not produced by the donor (Table 1 ) . In the first 6 months after BMT, nine of them showed a fast decrease of IgGl of recipient origin (Fig 2) . However, as shown in Fig  2 and Table 4 , IgG I of recipient G 1 m allotype still persisted at 1 year after BMT in I O of 12 recipients at a proportion above the cut-off level (Table 3) of the corresponding Glrn allotype in negative individuals. Seven of these 10 recipients could be investigated later than I year after BMT, and all of them showed persistence of recipient-derived IgG 1 at last follow up at 3 to 8 years after BMT (Table 4) . For Eight BM graft recipients from our study group were homozygous for G lm allotypes and had Glm allotype heterozygous donors. In all of these recipients, the distribution of Glm allotypes at 3 to 6 months after BMT fell within the range of heterozygous individuals (data not shown). Given this range, persistence of IgGl production by cells of recipient origin could neither be demonstrated nor excluded in these recipients.
Regarding IgG2, eight recipients who were heterozygous or homozygous for G%m(n) had a G2m(..) donor. In five of them, IgG2 expressing the G2m(n) allotype could be de- (Table 4) .
To investigate whether the occurrence of GVHD eliminates residual host-type IgG-producing cells, we analyzed the recipients with and without acute GVHD >grade 2 being transplanted for leukemia or SAA, separately. In four of six recipients who developed acute GVHD, the presence of IgG of recipient origin could be investigated until 1 to 8 years (mean, 4.5 years) after BMT; only in one of them did IgG of recipient type persist at a substantial level, ie, above the background of homozygous negative controls, until last fol- Persistence of lgGl of recipient origin after allogeneic BMT recipient homozygous (0) or heterozygous 10) for Glm(a), with a Glmlal-negative donor; recipient homozygous (01 or heterozygous (01 for Glm(f), with a Glm(f)-negative donor; recipient heterozygous (C!) for Glm(z1, with a Glm(zl-negative donor. %, proportion of lgGl with the relevant G l m allotype relative to the total amount of IgG1. The ranges of the proportions in individuals negative for Glmlz) (--l, Glm(a), and Glmlf) l--1, respectively, are shown (see also low up at 8 years after BMT. In 7 of 13 assessable recipients without GVHD >grade 2, host-type IgG persisted up to the time of last follow up, ie, from l to S years after BMT. In addition, at l year after BMT, the proportion of IgGl or IgG2 of recipient origin (after subtracting the background value for the corresponding Gm allotype in homozygous negative individuals, see Table 3 ) still present in the serum of recipients with acute GVHD >grade 2 (mean ? SD, 8.0% ? 6.5%) was lower than that in recipients without acute GVHD (mean Ifr SD, 20.5% +. 16.7%). Only two informative recipients in our study group developed extensive chronic GVHD. In one of them (recipient S), IgG2 of recipient origin was detectable at 1 year after BMT, but was absent from the serum at last follow up S years after BMT. The serum of the other recipient (recipient 22) contained a small amount of recipient-type IgGl at last follow up, 1 year after BMT.
Determination of the Gm allotype of H-IgG. H-IgG of low concentration were detected and characterized for their IgG subclass and Gm allotype by WIBL. Twelve of the BM donors expressed informative Gm allotypes, ie, Gm allotypes that were absent from the Gm phenotype of the recipient.
As shown in Table 5 , H-IgG with a Gm allotype exclusively present in the Gm phenotype of the donor were found in 9 of 11 investigated recipients. The frequency of these informative H-IgG in relation to the total number of H-IgG slightly increased over time after BMT (ie, 26%, 47%, and 50% at 3 to 9 weeks, 3 to 9 months, and 1 year post-BMT, respectively; data not shown). It should be noted that the remaining H-IgG in these recipients were of indiscriminant origin, because they expressed Gm allotypes shared between the donor and the recipient. H-IgG of donor Gm allotype could already be detected at 3 weeks after BMT and later. The appearance of H-IgG of donor Gm allotype early after BMT, eg, in the serum of BM graft recipient 12, is shown in Fig 3. H-IgG of donor allotype were also temporarily observed in the recipient with graft rejection (recipient 9). In four cases, H-IgG of donor origin appeared during or within I month after the period of plasma transfusions and/ or Ig suppletion (Tables 1 and S) .
Eighteen of the BM graft recipients of our study group expressed Gm allotypes that were absent from the donor. In 13 of them, H-IgG of recipient origin were detected ( Table  5 ). The kinetics of their appearance was quite variable, in that they were already present in seven recipients within 6 weeks after BMT, whereas in the other six cases, H-IgG of recipient origin were only detected several months after BMT. The relative frequency of H-IgG of recipient Gm allotype remained unchanged with time after BMT, ie, 43%, 36%, and 39% of the total number of H-IgG during the same periods as indicated above (data not shown).
DISCUSSION
The pattern of chimerism within cells of the B-cell lineage after allogeneic BMT has mostly been analyzed at the cellular level, ie, in cells from the peripheral blood, either by the amplification of variable number of tandem repeats through polymerase chain reaction in B cells isolated by fluorescence-activated cell sorting (FACSPCR-VNTR [FPV] ) or by in situ hybridization of the Y-chromosome in fluorescence-stained B cells in the case of sex difference between donor and recipient.22.23 Using the former technique, a persistent mixed chimerism of the B-cell population after BMT was found in the two patients transplanted for {severe) combined immunodeficiency ([SICID) in our study group. Reports on the analysis of chimerism at the product level (eg, by the determination of Gm allotypes present on secreted Ig or antibodies) are scarce, probably because these markers show a low polymorphism and are noninformative in the majority of donor-recipient c o~p l e s .~-~.~'~~ Interestingly, some investigators who performed combined studies at the cellular and the product level noted a discrepancy between the results obtained by these two appro ache^.^" They described several cases in which the peripheral blood B cells were exclusively of donor origin, whereas Gm allotypes of the recipient were present in the serum for years after BMT. These findings were interpreted as an indication of the persistence of sessile plasma cells of recipient origin in the bone marrow.
The aim of the present study was to investigate the extent to which IgG of recipient origin persisted after allogeneic BMT. Therefore, assays for the quantification of Gm allotypes in serum had to be developed. Furthermore, we investigated whether the H-IgG observed after allogeneic BMT were produced by B cells of donor or recipient origin. Results on the characterization of H-IgG obtained in a limited number of recipients from our study group have been reported earlier."
In 15 of 18 informative recipients (83%) a substantial part of IgGl andor IgG2 of recipient origin remained at last follow up 2 1 year after BMT. Long-term persistence of recipient-type Ig after allogeneic BMT has also been reported by others in smaller groups of BM graft recipie n t~.~.~ However, only Petz et al' made an estimation of the contribution of Ig of recipient origin to the total amount of Ig. Using HAI, they detected about 3% to 6% of host-type Ig in four recipients investigated 1 to 3 years after BMT, which is considerably lower than the percentage found in most of the recipients of our study group. Our study group consisted of children with (S)CID, SAA, and leukemia who were pretreated before BMT with different regimens (Table 1) . Excluding the (S)CID patients, persistence of Ig of recipient origin at 1 year after BMT was found in 11 of 13 informative recipients who received a myeloablative pretreatment; ie, in seven of seven patients with leukemia pretreated with high-dose total body irradiation (TBI, 8.0 Gy) and in four of six patients with leukemia after a TB1 dose 57.5 Gy, and in three of four patients with SAA who received nonmyeloablative conditioning.
Our conclusion from these data is that at least a fraction of Ig-producing cells of recipient origin is not eradicated by the pretreatment, independently of the cytoreductive regimen applied. Interestingly, Hibi and Dosch" and Hibi et alZu have reported that the human bone marrow contains a population of lymphoblastoid B cells that spontaneously produces IgG and IgA and is characterized in vitro by insensitivity to irradiation, corticosteroids, and cyclosporine A. It is attractive to speculate that these lymphoblastoid B cells represent a population of long-lived memory cells generated in the peripheral lymphoid tissues and recirculated to the bone marrow. In contrast, we have reported recently that the pattern of chimerism of the peripheral blood mononuclear cells during the first year after BMT for leukemia strongly depends on the intensity of the conditioning regimen.3" Persistence of host-type hematopoiesis, ie, stable mixed chimerism in all cell lineages including the B cells, was frequently observed after low-dose TB1 (57.5 Gy), but not after higher TB1 doses. These observations point to the different sensitivities of peripheral blood B cells and other, yet undefined, cells of the B-cell lineage to the regimens used for pretreatment of the BMT recipients.
It has been reported that acute GVHD is reduced in intensity and severity in patients with SAA with a transient mixed hematopoietic chimerism after allogeneic BMT." We could VAN TOL ET AL not reproduce this finding in a group of transplanted leukemia patients") or in the present study group: only six recipients developed an acute GVHD >grade 2 (Table l) , and in 17 of 20 analyzed recipients transplanted for leukemia or SAA, the B-cell population appeared to be completely of donor origin within 1 year after BMT. This was assessed by chromosomal analysis of mononuclear cells from bone marrow andor blood and by Y-chromatin staining of surface-labeled B cells.' or FPV analysis of separated B cells." Three recipients showed a transient mixed chimerism early after BMT, which became to a complete donor pattern in two cases (recipients I 1 and 19) and a complete recipient pattern in the one recipient (recipient 9) with recovery of autologous hematopoiesis. Although the frequency of the occurrence of acute GVHD >grade 2 was low in our study group, IgG of recipient origin was present after BMT at a slightly smaller proportion in recipients who developed GVHD, than in those without GVHD. These results suggest. but do not prove, that sessile IgG-producing cells of host origin might be eliminated by alloreactive, GVHD-inducing T cells derived from the donor.
In nine recipients with a donor expressing Gm allotypes that were not present in the recipient, H-IgG of the informative allotype appeared after BMT indicative for the donor origin of these H-IgG. In four cases, the appearance of donorderived H-IgG within 3 months after BMT indicated the engraftment of the B-cell lineage. During this early period after BMT, determination of the origin of the B-cell population using Gm allotype determination by HA1 or quantitative assays could have been blurred by plasma transfusions and/ or Ig suppletion. In 13 recipients who expressed Gm allotypes that were absent from the donor, H-IgG of host origin were found after BMT. There was no association between the detection of host-type H-IgG 1 or H-IgG2 and the proportion of host-derived IgGl or IgG2 relative to the total amount of the corresponding IgG subclasses. This finding indicates that IgG of recipient origin is not commonly produced by a limited number of persisting plasma cell clones.
In conclusion, a substantial part of serum IgG remained of recipient origin in a surprisingly high proportion of recipients, despite the fact that the circulating B cells were of donor origin at that time. The pretreatment regimens applied had no effect on this phenomenon, but GVHD seemed to suppress host-origin Ig production. These findings may be relevant for the evaluation of patients who have received allogeneic BMT for the treatment of multiple myeloma."2'3s The achievement of complete remission, defined as the absence of paraprotein in serum and of free Ig light chains in urine and the presence of less than 5% plasma cells in the bone marrow, may be delayed up to months or even years after allogeneic BMT.".3'.3h On the other hand, the occurrence of late relapse after achieving complete remission according to these conventional criteria has been observed."." This observation points to the possibility that clonal deviation in multiple myeloma takes place at an early stage of Bcell differentiation" or that the techniques applied to detect residual paraproteinemia are not sensitive enough. Usually, the presence of a paraprotein in the serum has been determined by immunofixation, which has a detection limit of 50
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
